Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Cardiovascular Diseases Clinical Trial

Official title:

A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 High-dose in Healthy Volunteers Under Fasting Conditions

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04906798
• Other study ID #: A88_10BE2109
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 4, 2021
• Est. completion date: July 23, 2021

Study information

• Verified date: May 2021
• Source: Chong Kun Dang Pharmaceutical
• Contact: Min-Gul Kim, Professor
• Phone: +82632593480
• Email: mgkim[@]jbcp.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers under Fasting Conditions

Description:

A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 high-dose in healthy volunteers under fasting conditions

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: July 23, 2021
• Est. primary completion date: July 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 54 Years

Eligibility

Inclusion Criteria:

1. Healthy adults age=19 years and age<55 years at the time of screening

2. Individuals who had 17.5 kg/m2 = Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight = 55 kg, women's total body weight = 45 kg

• BMI = Weight(kg)/ Height(m)2

3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years

4. Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening

5. Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product

6. Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion

7. Individuals with the ability and willingness to participate the entire study period

Exclusion Criteria:

1. Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)

2. Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug

3. Subject who shows the following values as a result of laboratory tests

*ALT or AST > 2 times upper limit of normal range

4. Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening

5. Subject who smokes more than one pack of cigarette a day within 6 months of screening

6. Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug

7. Subject who conform to the specific items below

• systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position

• Severe bradycardia (less than 50 beats/minute)

8. Subject who has significant alcohol abuse or drug abuse within a year of screening

9. Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug.

10. Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug.

11. Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug

12. Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself.

13. Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

14. Subjects who were deemed inappropriate to participate in the study by the investigator

Related Conditions & MeSH terms

• Cardiovascular Diseases

Intervention

Drug:
• CKD-385
Test Drug
• D744
Reference Drug

Locations

Country	Name	City	State
Korea, Republic of	Chonbuk National University Hospital	Jeonju

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt of CKD-385	Area under the concentration-time curve from time zero to time of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Secondary	AUCinf of CKD-385	Area under the concentration-time curve from zero up to infinity of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Secondary	Tmax of CKD-385	Time to maximum plasma concentration of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Secondary	T1/2 of CKD-385	Terminal elimination half-life of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Secondary	CL/F of CKD-385	Apparent clearance of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Secondary	Vd/F of CKD-385	Apparent Volume of Distribution of CKD-385	Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours